[Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C]

Details

Serval ID
serval:BIB_91F6062F322D
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
[Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C]
Journal
Rev Med Suisse
Author(s)
Girardin F., Goossens N., Vernaz N., Negro F.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
2015
Volume
11
Number
484
Pages
1610-2, 1614-6
Language
french
Notes
Girardin, F
Goossens, N
Vernaz, N
Negro, F
fre
English Abstract
Switzerland
Rev Med Suisse. 2015 Sep 2;11(484):1610-2, 1614-6.
Abstract
New direct-acting antivirals (DAA) against hepatitis C virus (HCV) have led to a therapeutic revolution in HCV management and virological cure rates approaching 100% while potentially avoiding significant complications of HCV (first cause of liver transplantation). We estimated the price of sustained virological response (SVR) depending on treatment strategy and patient profile. Costs of treatment with recent DAAs being so high, the accessibility to those drugs for the majority of subjects is hitherto limited to advanced stages of hepatitis C. This current situation increases the inequity and strengthens the dominant position of insurers and pharmaceutical companies with a rationing of care. We suggest herein global approaches from a population-level and health-care perspective aiming to reduce the prevalence, morbidity, and mortality related to HCV.
Keywords
Antiviral Agents/*economics/*therapeutic use, Hepatitis C, Chronic/*drug therapy/*economics, Humans, *Reimbursement Mechanisms
Pubmed
Create date
10/02/2021 12:32
Last modification date
11/02/2021 7:26
Usage data